Eusa acquires Asparec development rights from Alizé Pharma

Asparec is a recombinant, pegylated Erwinia chrysanthemi-derived asparaginase, and is currently in Phase I development for the treatment of ALL patients with hypersensitivity to standard-of-care.

As per the agreement, Eusa will pay Alizé Pharma an upfront fee, regulatory milestone payments and royalties on future product sales.

Preclinical data suggested that Asparec is potentially long acting and less immunogenic than currently available asparaginase Erwinia chrysanthemi.

Eusa Pharma president and CEO Bryan Morton said the deal follows the approval of company’s first internally developed product, and further underlines its strategic transition into a fully fledged development as well as commercialization organization.

Alizé Pharma president and founder Thierry Abribat said the agreement validates the company’s medical approach and emphasizes its drug development capabilities.